Imreplys is a medicine used to treat people of all ages who have been exposed to high levels of radiation over a short period, resulting in bone marrow damage and development of haematopoietic sub\-syndrome of acute radiation (H\-ARS). Patients with H\-ARS cannot produce enough new blood cells. This results in: * low white blood cell counts, increasing the risk of infections; * low red blood cell counts, leading to anaemia; * low platelet (components that help the blood to clot) counts, which increases the risk of bleeding. The medicine should be used in accordance with official radiological or nuclear emergency recommendations. Imreplys contains the active substance sargramostim.
Therapeutic Indication
Imreplys is indicated for treatment of patients of all ages acutely exposed to myelosuppressive doses of radiation with Haematopoietic Sub\-syndrome of Acute Radiation Syndrome (H\-ARS). Imreplys should be used in accordance with official radiological/nuclear emergency recommendations.
Therapeutic Area (MeSH)
ATC Code
L03AA09
ATC Item
N/A
Pharmacotherapeutic Group
Immunostimulants
Active Substance (Summary)
INN / Common Names
EMA Name
Imreplys
Medicine Name
Imreplys
Aliases
N/ANo risk management plan link.
